Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now ...
Regis Corporation (NasdaqGM: RGS), a leader in the haircare industry, today announced financial results for the first fiscal quarter ended September 30, 2025.
Launches New High-Performing XTM Mining Products to Support Revenue Growth in Q4 2025 Initiates ETH Staking with FalconX with Initial 1,000 ETH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback